Fagron announced first-quarter revenue of €263.4 million, representing a 10.3% increase from the same period a year earlier, the Belgium and Netherlands-based pharmaceutical compounding company said on Thursday.
On an organic basis and at constant exchange rates, Fagron reported growth of 3.2%, with the firm noting positive contributions across all of its geographic regions.
Latin America was a notable driver, delivering 10.4% organic growth at constant exchange rates, which the company attributed to the continued momentum of its Brands strategy in Brazil. The EMEA region also supported the topline expansion during the quarter.
During the period, Fagron completed the acquisition of Pharmavit in the Netherlands; the company said integration is progressing as planned and that the transaction contributed to overall revenue growth for the quarter.
Looking ahead to the full year 2026, Fagron set out its expectations for organic sales growth at constant exchange rates in the mid- to high-single digits. The company also projected a REBITDA margin of approximately 20% for the year, and indicated it expects the second half of 2026 to outperform the first half.
Fagron said it anticipates an acceleration in its business beginning in the second quarter, with stronger performance foreseen in the latter half of the year.
Financial and operational context
- Reported Q1 revenue: €263.4 million - up 10.3% year-over-year.
- Organic growth at constant exchange rates: 3.2%, with all regions contributing positively.
- Latin America organic growth at constant exchange rates: 10.4%, supported by the Brands strategy in Brazil.
- Acquisition completed: Pharmavit in the Netherlands - integration described as progressing as planned.
- 2026 outlook: mid- to high-single digit organic sales growth (constant exchange rates) and an approximate 20% REBITDA margin, with the second half expected to be stronger than the first.
The company emphasized timing for stronger momentum, stating that it expects business acceleration to begin in the second quarter and intensify into the second half. Beyond the figures and the acquisition update, Fagron reiterated its full-year targets for 2026 and highlighted regional performance drivers without providing further quantitative detail on segment-level margins or country-level breakdowns.